Results 171 to 180 of about 68,346 (260)

Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP.
Julie Sommet   +16 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Mechanisms of Thrombocytosis in Iron‐Deficiency Anemia

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Iron‐deficiency anemia is frequently accompanied by reactive thrombocytosis, yet the mechanisms underlying this association remain incompletely understood. Beyond impaired erythropoiesis, iron availability has emerged as an active regulator of hematopoietic lineage decisions.
João Vitor Facco   +2 more
wiley   +1 more source

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

open access: yesEuropean Journal of Haematology, EarlyView.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri   +11 more
wiley   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

open access: yesHaemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy